Company Description
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases.
Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs.
The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1.
It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1.
The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017.
Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
| Country | United States |
| IPO Date | Oct 29, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 177 |
| CEO | Dipal Doshi |
Contact Details
Address: 6 Tide Street Boston, Massachusetts United States | |
| Website | https://www.entradatx.com |
Stock Details
| Ticker Symbol | TRDA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001689375 |
| CUSIP Number | 29384C108 |
| ISIN Number | US29384C1080 |
| Employer ID | 81-3983399 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dipal Doshi | Chief Executive Officer & Director |
| Kory James Wentworth CPA | Chief Financial Officer & Treasurer |
| Nathan J. Dowden | President & Chief Operating Officer |
| Dr. Jared Cohen J.D., Ph.D. | General Counsel |
| Dr. Natarajan Sethuraman Ph.D. | President of Research & Development |
| Karla MacDonald | Chief Corporate Affairs Officer |
| Kerry Robert M.S. | Senior Vice President of People |
| Kevin Healy Ph.D. | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 12, 2024 | 4 | Filing |
| Dec 12, 2024 | 4 | Filing |
| Dec 03, 2024 | 4 | Filing |
| Dec 03, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 13, 2024 | 4 | Filing |
| Nov 13, 2024 | 4 | Filing |
| Nov 06, 2024 | 4 | Filing |
| Nov 05, 2024 | 10-Q | Quarterly Report |
| Nov 05, 2024 | 8-K | Current Report |